Stock on Focus: Corium International, Inc. (CORI)

Company Profile:

Corium International, Inc. is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules. Its Corplex and MicroCor platforms address the shortcomings of traditional transdermal drug delivery. Its marketed products include Clonidine TDS, which is a treatment for hypertension; Fentanyl TDS, which is a treatment for management of chronic pain, and Crest Whitestrips are a series of five products for oral care. Its Twirla is designed to deliver both hormones at levels comparable to low-dose oral contraceptives. Its MicroCor hPTH(1‑34) is a transdermal system designed to use its MicroCor technology to provide the delivery of parathyroid hormone. The company was incorporated in 1995 and is headquartered in Menlo Park, California.

Recent News:

Corium reported total revenues in the second quarter of fiscal 2016 of $7.0 million, compared with $11.3 million in the second quarter of fiscal 2015, and for the six-month period ended March 31, 2016 reported total revenues of $14.5 million, compared with $21.1 million in the same period of fiscal 2015.

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

@@@@@

Conclusion:

CORI’s strengths can be seen in its better growth. Technical indicators signal the bullish signs, as there is a bullish cross in MACD and Stotistic Oscillator. RSI is increasing to 53.10. The P/BV ratio indicates it is undervalued compared to the average P/BV ratio of the industry and the sector. We rate Corium International, Inc. (CORI) a STRONG BUY.